ARTICLE | Clinical News

Inactine: Phase I data; Phase II

December 4, 2000 8:00 AM UTC

In VITX's Phase I crossover trial of 12 healthy volunteers, 24-hour recovery of red blood cells (RBCs) treated with Inactine was comparable to that of untreated control RBCs, and long-term (28 day) survival of all blood units was normal. Infusions of treated RBCs were well tolerated, with no reactions or changes in biochemical parameters. RBC processing losses with Inactine treatment were <20 percent, VITX said. Data were presented at the American Society of Hematology meeting in San Francisco. ...